Off-the-Shelf cell therapy takes on tough leukemia
NCT ID NCT07491263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new 'universal' cell therapy (QH103) for people with a hard-to-treat type of leukemia (B-ALL) that has come back or not responded to standard treatment. The therapy uses donor immune cells engineered to target cancer cells, given after chemotherapy to prepare the body. Only 6 participants will be enrolled to check safety and tolerability first.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QH103 Cell Injection (CD19 CAR-γδ T cells) with cyclophosphamide and fludarabine
What this could lead to
If it works, this could point toward a more accessible 'off-the-shelf' cell therapy for hard-to-treat leukemia, reducing the need for patient-specific treatments.
What could go wrong
This is a very early Phase 1 trial with only 6 people, focused on safety, not effectiveness. The therapy may not work, and there are risks like severe immune reactions or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY CD19-POSITIVE B-ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The first affiliated hospital of fujian medical university
Fuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••